Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio
Executive Summary
Novartis' decision to expand its sales force by 1,000 reps in the U.S. - in the face of cuts by many of its competitors - reflects the growth potential of the firm's product portfolio and the strength of its pipeline, Pharmaceuticals CEO Thomas Ebeling said
You may also be interested in...
Novartis Gets By With A Little Help From Its Hypertension Franchise
Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call
Novartis Gets By With A Little Help From Its Hypertension Franchise
Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call
Wyeth, Schering Highlight Potential Of Part-Time Reps; Merck Remains Wary
Part-time sales representatives are useful as a supplement to, rather than a replacement for, a full-time sales force